Founded in 2000, Herborium Group, Inc. is a Botanical Therapeutics® company that trades on the Pink Sheets. For the industry, botanical therapeutics provide a value added approach based on product differentiation, higher profit margins, and intellectual property protection with a lower risk and regulatory burden and lower cost. Herborium Group, Inc. has their headquarters in Teaneck, New Jersey.

The Company focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. Herborium harvests their therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical, and marketing strategies to successfully introduce the products into Western markets.

Herborium’s business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals. They use clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Botanical Therapeutics bring the intellectual property value, posology, clinical validation, and rapid market entry while maintaining a safety profile of botanical ingredients and offering the benefits of preventive medicine and cost containment.

The Company secured a pipeline of botanical ingredient based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women’s Health, and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. The longer-term pipeline includes an arthritis candidate and an anti-infectious product candidate focused on antibiotic resistant infections.

Last week, Herborium Group, Inc. announced that they are partnering with the retail division of the major Portal Technology provider, Adrecom. This is to distribute their botanical therapeutic, AcnEase®, for Acne and Rosacea in Israel with expected $500,000 plus in revenues over the next 36 months. This partnership furthers the Company’s efforts to become the global leader in Natural Acne Treatment and Preventative Therapy. Herborium expects to enter the market by the end of the second quarter of 2011.

Prior to this announcement, in November, Herborium Group, Inc. announced that Gents, AB of Helsingborg, Sweden, renewed their distribution agreement to supply AcnEase® throughout Sweden.